Formycon

Gedeon Richter Becomes Strategic Investor of Formycon

Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.

Topics • Technology

Chances and Hurdles for Biosimilars

Top-Feature

Easyfairs Deutschland GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

SchüllerConsulting

Formycon

Gedeon Richter Becomes Strategic Investor of Formycon

Chances and Hurdles for Biosimilars

Top-Feature

Leading the way. Driving results.

API Manufacturing

Driving Sustainability Through Collaboration

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Brenntag Downsizes Management Board, Retains Both Divisions

Anchored in Sustainability

Leading Transformation

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Expert Insights

Dual‑Targeting Breakthroughs

Newsletter & e-edition